# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001437749-23-000954
**Filing Date:** 2023-1
**Character Count:** 12276
**Document Hash:** 3797a829d2ed7885abe402c4e1ed26cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-000954.hdr.sgml**: 20230112

**ACCESSION NUMBER**: 0001437749-23-000954

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230112

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230112

**DATE AS OF CHANGE**: 20230112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Isoray, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 411458152
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 23526022

**BUSINESS ADDRESS:**
- **STREET 1:** 350 HILLS STREET,
- **STREET 2:** SUITE 106
- **CITY:** RICHLAND
- **STATE:** WA
- **ZIP:** 99354
- **BUSINESS PHONE:** (509) 375-1202

**MAIL ADDRESS:**
- **STREET 1:** 350 HILLS STREET,
- **STREET 2:** SUITE 106
- **CITY:** RICHLAND
- **STATE:** WA
- **ZIP:** 99354

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

isr20230111_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

 **WASHINGTON, DC 20549**

**FORM **8-K**

**CURRENT REPORT PURSUANT TO** 

**SECTION 13 OR 15(D) OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

---

| | | |
|:---|:---|:---|
| Date of report (Date of earliest event reported): January 12, 2023 | Date of report (Date of earliest event reported): January 12, 2023 | Date of report (Date of earliest event reported): January 12, 2023 |
| **<u>Isoray, Inc.</u>**<br> (Exact Name of Registrant as Specified in Charter) | **<u>Isoray, Inc.</u>**<br> (Exact Name of Registrant as Specified in Charter) | **<u>Isoray, Inc.</u>**<br> (Exact Name of Registrant as Specified in Charter) |
| **<u>Delaware</u>**<br> (State or Other Jurisdiction<br> of Incorporation) | **<u>001-33407</u>**<br> (Commission<br> File Number) | **<u>41-1458152</u>**<br> (IRS Employer<br> Identification No.) |

---

**<u>350 Hills Street</u><u>, **<u>Suite 106</u>**, **<u>Richland</u>**, **<u>Washington</u> <u>99354</u>**</u>**

(Address of Principal Executive Offices) (Zip Code)

**<u>(**<u>509</u>**) **<u>375-1202</u>**</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value | ISR | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On January 12, 2023, the Company held its adjourned Fiscal 2023 Annual Meeting of Stockholders (the "<u>Annual Meeting</u>") to announce the second adjournment to January 27, 2023, of the Annual Meeting. No other business was conducted. The original Annual Meeting was held on December 13, 2022 and adjourned to January 12, 2023. A quorum was present at the meeting, whether in-person or by proxy, as required by the Company's Bylaws.

The Annual Meeting was partially adjourned again from January 12, 2023, to January 27, 2023, solely with respect to the voting on Proposal One. The Annual Meeting will resume solely with respect to Proposal One at 11 a.m. Arizona Time on January 27, 2023, at Gallagher & Kennedy, P.A., 2575 East Camelback Road, Suite 1100, Phoenix, Arizona 85016.

The voting results on Proposal One are set forth below.

<u>Proposal One</u> <u>–</u> <u>The Certificate Amendment Proposal</u>. Proposal One was to approve an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares of Common Stock. The Company had adjourned the Annual Meeting solely with respect to Proposal One to provide its stockholders additional time to vote on such proposal. The Company has further adjourned the Annual Meeting solely with respect to Proposal One to provide its stockholders additional time to vote on such proposal. The proposal is described in detail in the Definitive Proxy Statement filed by the Company on November 7, 2022. As of the date of the adjournment on January 12, 2023, the following votes had been cast on Proposal 1:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 67475410 | 13699439 | 828060 | 18357461 |

---

However, the affirmative vote of holders of more than 50% of the Company's issued and outstanding shares of Common Stock is necessary for Proposal One to be approved and the Company is still soliciting votes to reach the requisite number of votes required.

**Item 7.01 Regulation FD Disclosure**

On January 12, 2023, the Company issued a press release announcing the convening and partial adjournment of the Annual Meeting and the information for the reconvened Annual Meeting, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished in this Item 7.01 shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "<u>1934 Act</u>"), and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission, whether or not filed under the Securities Act of 1933, as amended, or the 1934 Act, regardless of any general incorporation language in such document.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 [Press Release dated January 12, 2023.](ex_463432.htm)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 12, 2023

Isoray, Inc., a Delaware corporation

By: <u>/s/ Lori A. Woods</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lori A. Woods, CEO

## Exhibit 99.1

**Exhibit 99.1**

![ex_463432img001.jpg](ex_463432img001.jpg)

**Isoray Announces Adjournment of Annual Meeting** 

**of Stockholders to January 27, 2023**

RICHLAND, WASHINGTON – January 12, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholders is being adjourned until January 27th, 2023, to provide stockholders who have not yet voted with additional time to vote on Proposal 1, approval of an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc.

The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services ("ISS") and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1. Proposal 1 approval is necessary for the consummation of the proposed merger with Viewpoint Molecular Targeting. Proposals 2 and 3 have already been approved and approval of these two proposals was also required to consummate the merger.

Stockholders' votes are very important and are critical for Isoray to move forward with the pending proposed merger with Viewpoint Molecular Targeting. Management believes that the pending proposed merger represents a transformational opportunity for Isoray and all its stockholders. It provides the Company with the opportunity to combine Isoray's existing business with a pipeline of very exciting products under development that have the potential to change the paradigm of patient care in the isotope space.

Proposal 1 requires an affirmative vote of a majority of the outstanding shares for passage. As of the January 12th meeting date, Proposal 1 had 67,475,410 shares voting in favor with an additional 3,580,974 shares required for approval. Approximately 82% of shares that have been voted are in favor of Proposal 1. Stockholders who do not vote are essentially opposing this proposal and as a result, the proposed merger.

------

Therefore, the company urges its stockholders who have not yet cast their vote to please do so. This will help save on further solicitation costs and ensure that stockholders' important votes are represented. Stockholders as of the October 20, 2022 record date can vote, even if they have subsequently sold their shares.

**Voting Instructions** – **For Shares Held in** "**Street**" **Name**

● To vote by telephone, please call the Company's proxy solicitor, Alliance Advisors LLC ("Alliance"), at (877) 728-5039. Alliance will assist with voting questions from 9 a.m. to 10 p.m. Eastern Time, Monday through Sunday.

● To vote by email, please contact Alliance at ISR <u>@allianceadvisors.com</u>.

**Contacts**

Investor Relations: Mark Levin (501) 255-1910

Media and Public Relations: Sharon Schultz (302) 539-3747

**About Isoray**

Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting <u>www.isoray.com</u>. Follow us on <u>LinkedIn</u> and <u>Twitter</u>.

**Safe Harbor Statement**

Statements in this news release about Isoray's future expectations, including: the ability to get the requisite vote in favor of Proposal 1 and the anticipated synergies and benefits of the proposed merger with Viewpoint Molecular Targeting, Inc., and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether there is sufficient time to get the votes, whether the proposed merger with Viewpoint Molecular Targeting, Inc. is completed and, if so, whether the anticipated benefits of the merger are realized. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.